Stock Updates

How has AstraZeneca PLC:(NYSE:AZN) performed recently?

AstraZeneca PLC (NYSE: AZN) is a large market cap stock with a market cap of 86685.12. It is in the Drug Manufacturers – Major industry and sector Healthcare, with a current P/E of 29.69, a forward P/E of 15.24 and EPS of 1.16. At a stock price of 34.22 (-0.20%) it has a dividend yield of 5.54%.

EPS growth for the last five years have been -16.70%, more recently this last year it has grown by 128.90%. The next year growth is going to be about -4.50% and more long-term -1.00% after five years. EPS growth quarter over quarter is 17.50%. Sales growth for the past five years have been -5.80% and sales growth quarter over quarter is 1.00%.

For performance, AstraZeneca PLC the past week has seen a gain of 12.32%. For the last month performance for AstraZeneca PLC is 17.88%. While the last quarter is 17.15% and half year, 13.35%. Finally for the year, performance is 8.68%.

The 52-week high for AstraZeneca PLC, is at -0.38%, and for the 52-week low it comes to a value of 26.88%. The 20-day simple moving average is 15.69% and 13.54% for the 200-day simple moving average.

Volatility for the week is at 2.56%, and for the month it is 1.60%. AstraZeneca PLC, has a target price of 34.66.

In terms of debt, long term debt/equity is 0.96, and for total debt/equity AstraZeneca PLC has 1.11. The gross margin is 82.80%, while operating margin is 17.00%, the profit margin is 11.80%. The current ratio is 0.8 and the quick ratio is 0.7.

Insider ownership is at 0.50%, with instituitional ownership at 11.00%. AstraZeneca PLC has a payout ratio of 121.20%. With the total shares outstanding coming to 2528. The shares float is 2503.73, with the float short at 1.01%, with short ratio coming to 4.56.

In terms of returns, the return on assets see AstraZeneca PLC, get 5.00%, with its returns on investment at 11.50%. Return on equity is 17.00%. So will the investors see the target price of 34.66, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Peter Clarke

Leave a Comment